Seeking Alpha

Galena Biopharma GALE +5.4%) moves up after releasing positive data from its phase 1/2 clinical...

Galena Biopharma GALE +5.4%) moves up after releasing positive data from its phase 1/2 clinical trial of tumor drug NeuVax. According to the trial, the drug showed a consistent reduction of circulating tumor cells in vaccinated patients. Final results will be reported at the San Antonio Breast Cancer Symposia in December 2012.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector